Real-World Study of PADN for the Treatment of PAH

Launched by PULNOVO MEDICAL (WUXI) CO., LTD. · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Pulmonary Artery Denervation (PADN) for people with Pulmonary Arterial Hypertension (PAH), a condition where high blood pressure affects the arteries in the lungs. The study is looking at how well this treatment works in real-life settings for patients who have already had the PADN procedure since March 2024.

If you have been diagnosed with PAH and have had the PADN treatment recently, you might be eligible to join. Participants need to be able to give permission for their health information to be used and must be willing to follow the treatment and attend follow-up visits. There are no specific age or gender restrictions, and no other major exclusions. Being part of the study means your health will be monitored to better understand how effective and safe PADN is for treating PAH outside of a clinical trial setting.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with PAH and received PADN procedure since March 2024.
• • 2. No contraindications to procedure.
• • 3. Able to provide informed consent and authorize use of health/research data.
• • 4. Compliant with treatment and follow-up requirements.
• Exclusion Criteria:
• • None specified.